Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?

Basit Öğe Kaydı
dc.contributor.authorKılıçkap, Saadettin
dc.contributor.authorBuğdaycı Basal, Fatma
dc.contributor.authorDemirkazık, Ahmet
dc.contributor.authorGürsoy, Pınar
dc.contributor.authorDemirci, Ufuk
dc.contributor.authorErman, Mustafa
dc.contributor.authorYumuk, Fulden
dc.contributor.authorÇay Şenler, Filiz
dc.contributor.authorÇakar, Burcu
dc.contributor.authorÇiçin, İrfan
dc.contributor.authorÖztürk, Akın
dc.contributor.authorCoşkun, Hasan Şenol
dc.contributor.authorÇubukçu, Erdem
dc.contributor.authorIşıkdoğan, Abdurrahman
dc.contributor.authorÖlmez, Ömer Fatih
dc.contributor.authorTatlı, Ali Murat
dc.contributor.authorKaraağaç, Mehmet Onur
dc.contributor.authorSakalar, Teoman
dc.contributor.authorEralp, Yeşim
dc.contributor.authorKorkmaz, Taner
dc.date.accessioned2019-12-24T12:15:18Z
dc.date.available2019-12-24T12:15:18Z
dc.date.issued2019
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.descriptionConference Conference: 44th Congress of the European-Society-for-Medical-Oncology (ESMO) Location: Barcelona, SPAIN Date: SEP 27-OCT 01, 2019 Sponsor(s):European Soc Med Oncol; Japanese Soc Med Oncol
dc.description.abstractBackground: ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK? patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK?patients who have Ple-I/E. Methods: In this multicenter study, patients with ALK? NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK?patients with NSCLC. Results: Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p¼0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p¼0.541). The rate of smokers was 43.4% (n¼157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p¼0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK?patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p¼0.008; 19.1% vs 4.8%, p¼0.002; 20.6% vs 8.9%, p¼0.003). The median PFS was longer in ALK? patients who have Ple-I/E 18.7 vs 10.6 months, p¼0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK?patients who have pleural involvement/infusion 44.6 vs 22.6 months, p¼0.051). The 1-, 2- and 3- year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement. Conclusions: Brain, liver and bone metastases are lower in ALK?patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK? NSCLC is associated with longer overall and progression-free survival. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
dc.description.sponsorshipEuropean Society for Medical Oncologyen_US
dc.description.sponsorshipJapanese Society of Medical Oncologyen_US
dc.identifier.citationKılıçkap, S., Buğdaycı Basal, F., Demirkazık, A., Gürsoy, P., Demirci, U., Erman, M. ... Korkmaz, T. (2019). Is there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?44th Congress of the European-Society-for-Medical-Oncology (ESMO) içinde (637-637. ss.). Barcelona, Spain, September 27-October 01, 2019.
dc.identifier.endpage637
dc.identifier.issn1569-8041
dc.identifier.issn0923-7534
dc.identifier.issueSupplement: 5
dc.identifier.startpage637
dc.identifier.urihttps://hdl.handle.net/20.500.12511/4651
dc.identifier.volume30
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.language.isoen
dc.publisherOxford University Press
dc.relation.ec0923-7534
dc.relation.ispartof44th Congress of the European-Society-for-Medical-Oncology (ESMO)en_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectALK-Positive
dc.subjectEffusion
dc.subjectPrognostic Significance
dc.titleIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
dc.typeConference Object

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
olmez-omerfaruk(2019).pdf
Boyut:
74.97 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Bildiri Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu